PMID- 16030191
OWN - NLM
STAT- MEDLINE
DCOM- 20051130
LR  - 20210206
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 106
IP  - 9
DP  - 2005 Nov 1
TI  - The incidence of heparin-induced thrombocytopenia in medical patients treated 
      with low-molecular-weight heparin: a prospective cohort study.
PG  - 3049-54
AB  - In contrast with extensive documentation in patients treated with unfractionated 
      heparin (UFH), the incidence of heparin-induced thrombocytopenia (HIT) in medical 
      patients receiving low-molecular-weight heparin (LMWH) is less well defined. In a 
      prospective cohort study, the platelet count was monitored in 1754 consecutive 
      patients referred to 17 medical centers and treated with LMWH for prophylaxis or 
      treatment of thromboembolic disorders. The diagnosis of HIT was accepted in case 
      of a platelet drop of at least 50%, the absence of obvious explanations for 
      thrombocytopenia, and the demonstration of heparin-dependent IgG antibodies. HIT 
      developed in 14 patients (0.80%; 95% CI, 0.43%-1.34%), in all of them within the 
      first 2 weeks, and was more frequent in patients who had (1.7%) than in those who 
      had not (0.3%) been exposed to UFH or LMWH (OR = 4.9; 95% CI, 1.5-15.7). The 
      prevalence of thromboembolic complications in HIT patients (4 of 14; 28.6%) was 
      remarkably higher than that (41 of 1740; 2.4%) observed in the remaining patients 
      (OR = 16.6; 95% CI, 5.0-55.0). Immune thrombocytopenia and related 
      thromboembolism may complicate the clinical course of medical patients treated 
      with LMWH with a frequency that is not different from that observed with the use 
      of UFH. The previous administration of heparin increases the rate of HIT.
FAU - Prandoni, Paolo
AU  - Prandoni P
AD  - Scienze Mediche e Chirurgiche, Clinica Medica II, Universita di Padova, Italy. 
      paoloprandoni@tin.it
FAU - Siragusa, Sergio
AU  - Siragusa S
FAU - Girolami, Bruno
AU  - Girolami B
FAU - Fabris, Fabrizio
AU  - Fabris F
CN  - BELZONI Investigators Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20050719
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Female
MH  - Heparin, Low-Molecular-Weight/*adverse effects/*therapeutic use
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Thrombocytopenia/*chemically induced/complications/pathology
MH  - Treatment Outcome
EDAT- 2005/07/21 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/07/21 09:00
PHST- 2005/07/21 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/07/21 09:00 [entrez]
AID - S0006-4971(20)68548-2 [pii]
AID - 10.1182/blood-2005-03-0912 [doi]
PST - ppublish
SO  - Blood. 2005 Nov 1;106(9):3049-54. doi: 10.1182/blood-2005-03-0912. Epub 2005 Jul 
      19.